TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples

Summary: Network pharmacology-based prediction of multi-targeted drug combinations is becoming a promising strategy to improve anticancer efficacy and safety. We developed a logic-based network algorithm, called Target Inhibition Interaction using Maximization and Minimization Averaging (TIMMA), which predicts the effects of drug combinations based on their binary drug-target interactions and single-drug sensitivity profiles in a given cancer sample. Here, we report the R implementation of the algorithm (TIMMA-R), which is much faster than the original MATLAB code. The major extensions include modeling of multiclass drug-target profiles and network visualization. We also show that the TIMMA-R predictions are robust to the intrinsic noise in the experimental data, thus making it a promising high-throughput tool to prioritize drug combinations in various cancer types for follow-up experimentation or clinical applications. Availability and implementation: TIMMA-R source code is freely available at http://cran.r-project.org/web/packages/timma/. Contact: jing.tang@helsinki.fi Supplementary information: Supplementary data are available at Bioinformatics online.

[1]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[2]  Armand Bankhead,et al.  Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. , 2013, Cancer research.

[3]  Bissan Al-Lazikani,et al.  canSAR: an integrated cancer public translational research and drug discovery resource , 2011, Nucleic Acids Res..

[4]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[5]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[6]  Adrian Duşa,et al.  A mathematical approach to the boolean minimization problem , 2008 .

[7]  Sébastien Lê,et al.  FactoMineR: An R Package for Multivariate Analysis , 2008 .

[8]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[9]  Tao Xu,et al.  Making Sense of Large-Scale Kinase Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis , 2014, J. Chem. Inf. Model..

[10]  Amar Koleti,et al.  Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS) , 2014, Journal of biomolecular screening.

[11]  X-S Zhang,et al.  Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs , 2014, CPT: pharmacometrics & systems pharmacology.

[12]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[13]  Krister Wennerberg,et al.  Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.

[14]  S. Vilar,et al.  High-Throughput Methods for Combinatorial Drug Discovery , 2013, Science Translational Medicine.

[15]  Tao Xu,et al.  Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..

[16]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..